Details for Patent: 9,403,772
✉ Email this page to a colleague
Which drugs does patent 9,403,772 protect, and when does it expire?
Patent 9,403,772 protects AKYNZEO and is included in one NDA.
This patent has sixty-six patent family members in forty-nine countries.
Summary for Patent: 9,403,772
| Title: | 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-tol- yl)pyridin-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium as a neurokinin receptor modulator |
| Abstract: | Compounds and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the neurokinin (NK.sub.1) receptor, based on 4-(5-(2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethylpropanamido)-4-(o-to- lyl)3yridine-2-yl)-1-methyl-1-((phosphonooxy)methyl)piperazin-1-ium and pharmaceutically acceptable salts thereof. |
| Inventor(s): | Fadini; Luca (Giubiasco, CH), Manini; Peter (Giubiasco, CH), Pietra; Claudio (Como, IT), Giuliano; Claudio (Como, IT), Lovati; Emanuela (Mendrisio, CH), Cannella; Roberta (Varese, IT), Venturini; Alessio (Varese, IT), Stella; Valentino J (Lawrence, KS) |
| Assignee: | HELSINN HEALTHCARE SA (Lugano/Pazzallo, CH) |
| Application Number: | 14/360,991 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,403,772 |
|
Patent Claim Types: see list of patent claims | Use; Compound; |
Drugs Protected by US Patent 9,403,772
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Helsinn Hlthcare | AKYNZEO | fosnetupitant chloride hydrochloride; palonosetron hydrochloride | POWDER;INTRAVENOUS | 210493-001 | Apr 19, 2018 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY | ⤷ Try a Trial | |||
| Helsinn Hlthcare | AKYNZEO | fosnetupitant chloride hydrochloride; palonosetron hydrochloride | SOLUTION;INTRAVENOUS | 210493-002 | May 27, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,403,772
| PCT Information | |||
| PCT Filed | November 28, 2012 | PCT Application Number: | PCT/US2012/066778 |
| PCT Publication Date: | June 06, 2013 | PCT Publication Number: | WO2013/082102 |
International Family Members for US Patent 9,403,772
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 089019 | ⤷ Try a Trial | |||
| Australia | 2012346133 | ⤷ Try a Trial | |||
| Brazil | 112014012878 | ⤷ Try a Trial | |||
| Canada | 2850644 | ⤷ Try a Trial | |||
| Chile | 2014001280 | ⤷ Try a Trial | |||
| China | 104053652 | ⤷ Try a Trial | |||
| China | 106518924 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
